<DOC>
	<DOCNO>NCT00835120</DOCNO>
	<brief_summary>The study open-label 8-week adjunctive trial pioglitazone acute relief bipolar depression comorbid metabolic syndrome/insulin resistance . Subjects experience partial full response option continue acute continuation phase last 12 week . The extension phase allow assessment safety tolerability pioglitazone acute continuation period .</brief_summary>
	<brief_title>Pioglitazone Treatment Bipolar Disorder Comorbid Metabolic Syndrome Insulin Resistance</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Be male female age 18 70 Diagnostic Statistical Manual Mental Disorders ( DSM ) IV diagnosis bipolar disorder ( type I , II , NOS ) Currently depress confirm MINIPlus screen visit Currently receive treatment antimanic drug Meets criteria metabolic syndrome insulin resistance Pregnancy breast feed Unstable inadequately treat medical illness judge investigator Severe personality disorder Serious suicidal risk Known history intolerance hypersensitivity pioglitazone Treatment pioglitazone 3 month prior randomization Dependence alcohol drug ( nicotine ) 3 month prior study entry Currently take antidiabetic/glucoselowering agent . Diagnosed dementia Acute Mania define Young Mania Rating Scale ( YMRS ) score &gt; 15 Diagnosed heart failure Transaminase elevation &gt; 2.5 time upper limit normal Presence renal impairment ( eg . creatinine &gt; 1.5 ) Fasting blood glucose &gt; 150 mg/dL Hb A1c &gt; 7.5 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>